- Title: Subtitle
- Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience
- Creators
- P. P. Breitfeld - Duke University Medical Center, Durham, NC; University of Nebraska Medical Center, Omaha, NE; University of Iowa, Iowa City, IA; Mayo Clinic, Rochester, MN; Childrens Hospital of Columbus, Columbus, OH; Memorial Sloan Kettering, New York, NY; University of Oklahoma, Oklahoma City, OKJ. Anderson - University of IowaS. Kao - University of IowaD. Rodeberg - University of IowaS. Qualman - Duke University Medical Center, Durham, NC; University of Nebraska Medical Center, Omaha, NE; University of Iowa, Iowa City, IA; Mayo Clinic, Rochester, MN; Childrens Hospital of Columbus, Columbus, OH; Memorial Sloan Kettering, New York, NY; University of Oklahoma, Oklahoma City, OKS. Wolden - University of IowaW. Meyer - Duke University Medical Center, Durham, NC; University of Nebraska Medical Center, Omaha, NE; University of Iowa, Iowa City, IA; Mayo Clinic, Rochester, MN; Childrens Hospital of Columbus, Columbus, OH; Memorial Sloan Kettering, New York, NY; University of Oklahoma, Oklahoma City, OK
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.22(14_suppl), pp.8513-8513
- DOI
- 10.1200/jco.2004.22.14_suppl.8513
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 07/15/2004
- Academic Unit
- Preventive and Community Dentistry; Radiology; Stead Family Department of Pediatrics
- Record Identifier
- 9984320008202771
Abstract
Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience
Journal of clinical oncology, Vol.22(14_suppl), pp.8513-8513
07/15/2004
DOI: 10.1200/jco.2004.22.14_suppl.8513
Details
Metrics
20 Record Views